David A Leske1, Sarah R Hatt1, Yolanda S Castañeda2, Suzanne M Wernimont1, Laura Liebermann1, Christina S Cheng-Patel2, Eileen E Birch3, Jonathan M Holmes4. 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA. 2. Retina Foundation of the Southwest, Dallas, Texas, USA. 3. Retina Foundation of the Southwest, Dallas, Texas, USA; Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 4. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: holmes.jonathan@mayo.edu.
Abstract
PURPOSE: To evaluate the recently developed Pediatric Eye Questionnaire (PedEyeQ) in visually impaired and visually normal children, as an initial validation of the PedEyeQ. DESIGN: Questionnaire validation study. METHODS: A total of 48 children with visual impairment (retinal, cortical, and corneal conditions) and 59 visually normal controls were enrolled at 2 centers. Five- to 17-year-old children completed the Child PedEyeQ (5-11- and 12-17-year-old versions), and parents completed the Proxy PedEyeQ (0-4-, 5-11-, and 12-17-year-old versions) and the Parent PedEyeQ. Rasch scores were calculated by age group for each distinct domain within each age-specific PedEyeQ (converted to 0-100 for interpretation). Domains for the Child PedEyeQ are functional vision, bothered by eyes/vision, social, and frustration/worry. Proxy PedEyeQ domains are functional vision, bothered by eyes/vision, social, frustration/worry, and eye care. Parent PedEyeQ domains are impact on parent and family, worry about child's eye condition, worry about child's self-perception/interactions, and worry about child's functional vision. For each domain, median PedEyeQ scores were compared between visually impaired and visually normal cohorts. RESULTS: Child 5-11 and 12-17 PedEyeQ scores were significantly lower (worse) for visually impaired children than for controls for each domain (P < .007), except for the social domain in 5-11-year-old children (P = .13). In addition, Proxy 0-4-, 5-11-, and 12-17-year-old PedEyeQ scores, and Parent PedEyeQ scores, were lower for visually impaired children across all domains (P < .001). CONCLUSIONS: Visually impaired children and their parents had significantly lower (worse) PedEyeQ scores than visually normal controls, across functional vision and eye-related quality of life domains, demonstrating known-group validity of the PedEyeQ in children with visual impairment.
PURPOSE: To evaluate the recently developed Pediatric Eye Questionnaire (PedEyeQ) in visually impaired and visually normal children, as an initial validation of the PedEyeQ. DESIGN: Questionnaire validation study. METHODS: A total of 48 children with visual impairment (retinal, cortical, and corneal conditions) and 59 visually normal controls were enrolled at 2 centers. Five- to 17-year-old children completed the ChildPedEyeQ (5-11- and 12-17-year-old versions), and parents completed the Proxy PedEyeQ (0-4-, 5-11-, and 12-17-year-old versions) and the Parent PedEyeQ. Rasch scores were calculated by age group for each distinct domain within each age-specific PedEyeQ (converted to 0-100 for interpretation). Domains for the ChildPedEyeQ are functional vision, bothered by eyes/vision, social, and frustration/worry. Proxy PedEyeQ domains are functional vision, bothered by eyes/vision, social, frustration/worry, and eye care. Parent PedEyeQ domains are impact on parent and family, worry about child's eye condition, worry about child's self-perception/interactions, and worry about child's functional vision. For each domain, median PedEyeQ scores were compared between visually impaired and visually normal cohorts. RESULTS:Child 5-11 and 12-17 PedEyeQ scores were significantly lower (worse) for visually impairedchildren than for controls for each domain (P < .007), except for the social domain in 5-11-year-old children (P = .13). In addition, Proxy 0-4-, 5-11-, and 12-17-year-old PedEyeQ scores, and Parent PedEyeQ scores, were lower for visually impairedchildren across all domains (P < .001). CONCLUSIONS:Visually impairedchildren and their parents had significantly lower (worse) PedEyeQ scores than visually normal controls, across functional vision and eye-related quality of life domains, demonstrating known-group validity of the PedEyeQ in children with visual impairment.
Authors: James R Drover; Joost Felius; Christina S Cheng; Sarah E Morale; Lauren Wyatt; Eileen E Birch Journal: J AAPOS Date: 2007-12-26 Impact factor: 1.220
Authors: Sarah R Hatt; David A Leske; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: Am J Ophthalmol Date: 2019-01-14 Impact factor: 5.258
Authors: Ying Pan; Kristina Tarczy-Hornoch; Susan A Cotter; Ge Wen; Mark S Borchert; Stanley P Azen; Rohit Varma Journal: Optom Vis Sci Date: 2009-06 Impact factor: 1.973
Authors: Sarah R Hatt; David A Leske; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2018-09-21 Impact factor: 1.220
Authors: Lauren N Ayton; Joseph F Rizzo; Ian L Bailey; August Colenbrander; Gislin Dagnelie; Duane R Geruschat; Philip C Hessburg; Chris D McCarthy; Matthew A Petoe; Gary S Rubin; Philip R Troyk Journal: Transl Vis Sci Technol Date: 2020-07-16 Impact factor: 3.283
Authors: David A Leske; Sarah R Hatt; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2020-02-28 Impact factor: 1.220
Authors: David A Leske; Sarah R Hatt; Suzanne M Wernimont; Yolanda S Castañeda; Christina S Cheng-Patel; Laura Liebermann; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2021-02-16 Impact factor: 1.220
Authors: Sarah R Hatt; David A Leske; Suzanne M Wernimont; Erick D Bothun; Eileen E Birch; Jonathan M Holmes Journal: J Binocul Vis Ocul Motil Date: 2022-02-01
Authors: David A Leske; Sarah R Hatt; Suzanne M Wernimont; Yolanda S Castañeda; Christina S Cheng-Patel; Laura Liebermann; Eileen E Birch; Jonathan M Holmes Journal: Am J Ophthalmol Date: 2020-10-28 Impact factor: 5.258
Authors: David A Leske; Sarah R Hatt; Yolanda S Castañeda; Suzanne M Wernimont; Christina S Cheng-Patel; Erick D Bothun; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2021-06-26 Impact factor: 1.325
Authors: Eileen E Birch; Yolanda S Castañeda; Christina S Cheng-Patel; Sarah E Morale; Krista R Kelly; Reed M Jost; Lindsey A Hudgins; David A Leske; Jonathan M Holmes Journal: Invest Ophthalmol Vis Sci Date: 2020-09-01 Impact factor: 4.799